Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by JPMorgan Chase & Co.

Charles River Laboratories International (NYSE:CRL) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report released on Thursday, MarketBeat.com reports. The brokerage currently has a $310.00 price target on the medical research company’s stock, up from their previous price target of $180.00. JPMorgan Chase & Co.‘s target price indicates a potential upside of 16.13% from the company’s current price.

Several other brokerages have also recently issued reports on CRL. Barclays reaffirmed an “overweight” rating and set a $300.00 target price on shares of Charles River Laboratories International in a research report on Wednesday. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Morgan Stanley upped their price objective on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $246.69.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $266.95 on Thursday. Charles River Laboratories International has a one year low of $144.26 and a one year high of $268.00. The firm has a 50 day simple moving average of $214.85 and a 200 day simple moving average of $189.25. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.03. The company has a market cap of $12.74 billion, a price-to-earnings ratio of -55.04, a PEG ratio of 2.92 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts predict that Charles River Laboratories International will post 11.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,264,241. The trade was a 51.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRL. Los Angeles Capital Management LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $42,000. Sfam LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at $43,000. Activest Wealth Management grew its stake in shares of Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $46,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.